title: Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study.
abstract: BACKGROUND
  Hemarthroses in severe hemophilia precipitate physical, psychosocial and financial difficulties.
  
  
  OBJECTIVE
  To compare the effects of secondary prophylaxis with on-demand sucrose-formulated recombinant factor VIII (rFVIII-FS) therapy in severe hemophilia A.
  
  
  METHODS
  This open-label study included patients aged 30-45 years with factor VIII (FVIII) coagulant activity < 1 IU dL(-1) who were using on-demand FVIII treatment. Patients were treated with rFVIII-FS on demand for 6 months, followed by 7 months prophylaxis (20-40 IU kg(-1), three times per week, with the first month considered a run-in). The primary endpoint was the number of hemarthroses.
  
  
  RESULTS
  Twenty patients were enrolled (n = 19 completed); the mean age was 36.4 years, and 16 had target joints. The median (25-75%) number of joint bleeds decreased significantly with prophylaxis [0 (0-3)] vs. on-demand [15 (11-26); P < 0.001] therapy. The number of all bleeds was 0 (0-3) vs. 20.5 (14-37; P < 0.001), respectively. Median (range) total Gilbert scores improved after prophylaxis [18 (3-39)] compared with on-demand [25 (4-46)] therapy, predominantly reflecting the improved bleeding score. Median time from last prophylactic infusion to bleed was 2 days; 82.5% of bleeds occurred 2-3 days after the last infusion. Median 48-h and 72-h FVIII trough levels measured during months 10 and 13 were consistently > 6 and > 4 IU dL(-1), respectively. Treatment was well tolerated, and no inhibitor formation was observed.
  
  
  CONCLUSIONS
  Secondary prophylaxis with rFVIII-FS significantly reduced the frequency of hemarthroses compared with on-demand therapy in adult patients with severe hemophilia A.
authors.affiliation: University Hospital of Wales, Cardiff, UK. peter.collins@cardiffandvale.wales.nhs.uk
authors.forename: P
authors.initials: P
authors.lastname: Collins
authors.forename: A
authors.initials: A
authors.lastname: Faradji
authors.forename: M
authors.initials: M
authors.lastname: Morfini
authors.forename: M M
authors.initials: MM
authors.lastname: Enriquez
authors.forename: L
authors.initials: L
authors.lastname: Schwartz
mesh_terms: D000328:Adult; D002626:Chemistry, Pharmaceutical; D003029:Coagulants / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D018592:Cross-Over Studies; D004334:Drug Administration Schedule; D005060:Europe; D005169:Factor VIII / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D006395:Hemarthrosis / Q000097:blood / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D006467:Hemophilia A / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D018718:Home Infusion Therapy; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D055502:Secondary Prevention; D012720:Severity of Illness Index; D013395:Sucrose / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D013997:Time Factors; D016896:Treatment Outcome; D014481:United States
chemical_list: D003029:Coagulants; C438308:recombinant FVIII, sugar formulated; D013395:Sucrose; D005169:Factor VIII